Small Cell Lung Cancer ( Sclc ) Clinical Trials
4 recruiting trials for Small Cell Lung Cancer ( Sclc ). Eligibility criteria explained in plain English.
TrialFinderData lists 4 Small Cell Lung Cancer ( Sclc ) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 75% (3 studies); the largest phase groups are Phase 1 / Phase 2: 3, Phase 1: 1.
Research is led by PMV Pharmaceuticals, Inc (1), Thena Biotech S.r.l. (1), Tasca Therapeutics (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is rezatapopt (drug, 1 trial), followed by pembrolizumab, THE-0504.
Track Small Cell Lung Cancer ( Sclc ) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or...
THE-0504 in Patients With Solid Tumors
Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with...
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if...
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Small Cell Lung Cancer ( Sclc ), with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Small Cell Lung Cancer ( Sclc ), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Small Cell Lung Cancer ( Sclc ), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.